DC
Therapeutic Areas
Akagera Medicines Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AKG‑TB‑LAI | Tuberculosis (multidrug‑resistant) | Phase 1 |
| AKG‑MRSA‑LAI | Methicillin‑resistant Staphylococcus aureus | Preclinical |
| AKG‑TB‑VAX | Tuberculosis vaccine | Preclinical |
| AKG‑Lassa‑VAX | Lassa fever vaccine | Preclinical |
| AKG‑HIV‑VAX | HIV vaccine | Preclinical |
| AKG‑RSV‑VAX | Respiratory syncytial virus vaccine | Preclinical |
| AKG‑Flu‑VAX | Influenza vaccine | Preclinical |
Leadership Team at Akagera Medicines
AL
Anne Lenaerts, PhD
Science Advisory Board Member
AD
Andreas Diacon, MD, PhD
Clinical Advisory Board Member